U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.
Shares of argenx SE – ADR (NASDAQ:ARGX) fell sharply in pre-market trading after the company discontinued its Phase 3 UplighTED studies of efgartigimod SC in thyroid eye disease following a futility review.
argenx shares dipped 6% to $825.00 in pre-market trading.
Here are some other stocks moving lower in pre-market trading.
Photo via Shutterstock